These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 24298066)

  • 1. Neoadjuvant therapy as a platform for drug development and approval in breast cancer.
    Bardia A; Baselga J
    Clin Cancer Res; 2013 Dec; 19(23):6360-70. PubMed ID: 24298066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Room for improvement in breast cancer clinical trial design: taking advantage of the preoperative setting.
    Kalinsky K; Hershman DL
    J Comp Eff Res; 2013 Jul; 2(4):393-403. PubMed ID: 24236681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical usefulness and relevance of intermediate endpoints for cytotoxic neoadjuvant therapy.
    Fontanella C; Loibl S; von Minckwitz G
    Breast; 2015 Nov; 24 Suppl 2():S84-7. PubMed ID: 26279131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons from the neoadjuvant setting on how best to choose adjuvant therapies.
    von Minckwitz G; Loibl S; Maisch A; Untch M
    Breast; 2011 Oct; 20 Suppl 3():S142-5. PubMed ID: 22015282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A note on breast cancer trials with pCR-based accelerated approval.
    Xia Y; Cui L; Yang B
    J Biopharm Stat; 2014; 24(5):1102-14. PubMed ID: 24926729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
    Generali D; Berruti A; Foroni C; Bazzola L; Andreis D; Allevi G; Bersiga A; Dogliotti L; Fox SB; Harris AL; Bottini A
    J Natl Cancer Inst Monogr; 2011; 2011(43):67-70. PubMed ID: 22043044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
    Metzger-Filho O; de Azambuja E
    J Natl Cancer Inst Monogr; 2011; 2011(43):116-9. PubMed ID: 22043056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Model for Testing Emerging Targeted Therapies in Breast Cancer.
    Esposito A; Criscitiello C; Curigliano G
    J Natl Cancer Inst Monogr; 2015 May; 2015(51):51-5. PubMed ID: 26063887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant and neoadjuvant therapy for gastric cancer.
    Kelsen DP
    Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
    Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
    Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SerpinB3, a new prognostic tool in breast cancer patients treated with neoadjuvant chemotherapy.
    Collie-Duguid ES; Sweeney K; Stewart KN; Miller ID; Smyth E; Heys SD
    Breast Cancer Res Treat; 2012 Apr; 132(3):807-18. PubMed ID: 21695460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2-positive early breast cancer and trastuzumab: a surgeon's perspective.
    Kulkarni S; Hicks DG
    Ann Surg Oncol; 2008 Jun; 15(6):1677-88. PubMed ID: 18398661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy in the treatment of breast cancer.
    Redden MH; Fuhrman GM
    Surg Clin North Am; 2013 Apr; 93(2):493-9. PubMed ID: 23464698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.
    Mauri D; Pavlidis N; Ioannidis JP
    J Natl Cancer Inst; 2005 Feb; 97(3):188-94. PubMed ID: 15687361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multidisciplinary approach to neoadjuvant therapy for primary operable breast cancer. Challenges and opportunities.
    Connolly R; Stearns V
    Oncology (Williston Park); 2010 Feb; 24(2):135-43. PubMed ID: 20361464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept.
    Iwata H
    Breast Cancer; 2011 Apr; 18(2):92-7. PubMed ID: 21140250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and future roles of neoadjuvant chemotherapy in operable breast cancer.
    Kim R; Osaki A; Toge T
    Clin Breast Cancer; 2005 Aug; 6(3):223-32; discussion 233-4. PubMed ID: 16137432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
    Kane RC; Farrell AT; Sridhara R; Pazdur R
    Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.